Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Allon Therapeutics Inc NPCUF

Allon Therapeutics, Inc. is a Canada-based Company, which develops treatments for neurodegenerative diseases. The Company is engaged in pre-clinical and clinical development of proprietary neuroprotective compounds which may be applied for the potential treatment of Alzheimer's Disease, Parkinson's Disease, senile dementia, glaucoma, traumatic head injury, neuronal damage due to stroke and other conditions involving neurodegeneration. The Company's drug, davunetide, is proceeding in a pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA).


GREY:NPCUF - Post by User

Post by retiredcfon Dec 09, 2017 7:53am
150 Views
Post# 27122950

Stephen Takacsy

Stephen TakacsyWill be on Market Call on Monday and as can be seen, one of his past picks will be NPC so we should get his views on whether he feels another offer is likely. GLTA

2016-12-12
 
TOP PICK
Napec Inc (NPC-T) 
 
An infrastructure play.  He came across this Quebec based company that provides services to gas and electricity companies with 80% in the North-East US.  They are benefitting from a huge infrastructure program.  The opportunities could grow as the US spends even more money on it.  They have long established operations in the US with stellar reputations for execution and safety.  No Dividend. (Analysts’ Target:  $1.60)
 
Chief Investment Officer & Portfolio Mgr, Lester Asset Management
 
Price: $0.940
Owned: Yes
<< Previous
Bullboard Posts
Next >>